Tags

Type your tag names separated by a space and hit enter

Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Jpn J Clin Oncol 2005; 35(9):514-9JJ

Abstract

OBJECTIVE

We conducted a retrospective analysis of prognosis factors for survival in breast cancer patients with 1-3 axillary lymph node metastases and tried to identify a subset of patients with good prognosis suitable for cyclophosphamide, methotrexate and 5-fluorouracil (CMF) adjuvant chemotherapy.

METHODS

A cohort of 446 breast cancer patients received definite surgery and adjuvant chemotherapy with CMF at Chang Gung Memorial Hospital from 1990 to 1998. They were enrolled in the study. The median follow-up time was 69 months. Prognostic factors including age, tumor size, number of involved nodes, steroid receptor status, tumor ploidy, synthetic-phase fraction, histologic grade and administration of tamoxifen were analysed for disease-free survival (DFS) and overall survival (OS) by Cox regression model.

RESULTS

The estimated 5 year OS and DFS for all patients were 85.4 and 71.5%, respectively. Multivariate analysis revealed that tumor size, age and estrogen receptor (ER) status were independent prognostic factors for OS, and tumor size, age, ER status and number of involved nodes were independent prognostic factors for DFS. The 5 year OS rates of the low-risk group (age >40, tumor < or =3 cm and positive ER) and average-risk group (either age < or =40, tumor >3 cm or negative ER) were 98.8 and 82.4%, respectively (P = 0.0001). The 5 year DFS of the low-risk and high-risk group were 88.2 and 67.7%, respectively (P = 0.0001).

CONCLUSION

Among breast cancer patients with 1-3 positive lymph nodes excellent survival rate was found in those who had favorable prognostic factors, including age >40, tumor size < or =3 cm and positive ER. Adjuvant chemotherapy with CMF regimen is optimal for these low-risk patients.

Authors+Show Affiliations

Division of Hematology/Oncology, Chang Gung Memorial Hospital, Taipei 105, Taiwan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16199422

Citation

Lin, Yung-Chang, et al. "Identifying Good Prognosis Group of Breast Cancer Patients With 1-3 Positive Axillary Nodes for Adjuvant Cyclophosphamide, Methotrexate and 5-fluorouracil (CMF) Chemotherapy." Japanese Journal of Clinical Oncology, vol. 35, no. 9, 2005, pp. 514-9.
Lin YC, Chen SC, Chang HK, et al. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy. Jpn J Clin Oncol. 2005;35(9):514-9.
Lin, Y. C., Chen, S. C., Chang, H. K., Hsueh, S., Tsai, C. S., Lo, Y. F., ... Chen, M. F. (2005). Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy. Japanese Journal of Clinical Oncology, 35(9), pp. 514-9.
Lin YC, et al. Identifying Good Prognosis Group of Breast Cancer Patients With 1-3 Positive Axillary Nodes for Adjuvant Cyclophosphamide, Methotrexate and 5-fluorouracil (CMF) Chemotherapy. Jpn J Clin Oncol. 2005;35(9):514-9. PubMed PMID: 16199422.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy. AU - Lin,Yung-Chang, AU - Chen,Shin-Cheh, AU - Chang,Hsien-Kun, AU - Hsueh,Swei, AU - Tsai,Chien-Sheng, AU - Lo,Yung-Feng, AU - Hwang,Tsann-Long, AU - Chen,Miin-Fu, PY - 2005/10/4/pubmed PY - 2005/12/13/medline PY - 2005/10/4/entrez SP - 514 EP - 9 JF - Japanese journal of clinical oncology JO - Jpn. J. Clin. Oncol. VL - 35 IS - 9 N2 - OBJECTIVE: We conducted a retrospective analysis of prognosis factors for survival in breast cancer patients with 1-3 axillary lymph node metastases and tried to identify a subset of patients with good prognosis suitable for cyclophosphamide, methotrexate and 5-fluorouracil (CMF) adjuvant chemotherapy. METHODS: A cohort of 446 breast cancer patients received definite surgery and adjuvant chemotherapy with CMF at Chang Gung Memorial Hospital from 1990 to 1998. They were enrolled in the study. The median follow-up time was 69 months. Prognostic factors including age, tumor size, number of involved nodes, steroid receptor status, tumor ploidy, synthetic-phase fraction, histologic grade and administration of tamoxifen were analysed for disease-free survival (DFS) and overall survival (OS) by Cox regression model. RESULTS: The estimated 5 year OS and DFS for all patients were 85.4 and 71.5%, respectively. Multivariate analysis revealed that tumor size, age and estrogen receptor (ER) status were independent prognostic factors for OS, and tumor size, age, ER status and number of involved nodes were independent prognostic factors for DFS. The 5 year OS rates of the low-risk group (age >40, tumor < or =3 cm and positive ER) and average-risk group (either age < or =40, tumor >3 cm or negative ER) were 98.8 and 82.4%, respectively (P = 0.0001). The 5 year DFS of the low-risk and high-risk group were 88.2 and 67.7%, respectively (P = 0.0001). CONCLUSION: Among breast cancer patients with 1-3 positive lymph nodes excellent survival rate was found in those who had favorable prognostic factors, including age >40, tumor size < or =3 cm and positive ER. Adjuvant chemotherapy with CMF regimen is optimal for these low-risk patients. SN - 0368-2811 UR - https://www.unboundmedicine.com/medline/citation/16199422/Identifying_good_prognosis_group_of_breast_cancer_patients_with_1_3_positive_axillary_nodes_for_adjuvant_cyclophosphamide_methotrexate_and_5_fluorouracil__CMF__chemotherapy_ L2 - https://academic.oup.com/jjco/article-lookup/doi/10.1093/jjco/hyi143 DB - PRIME DP - Unbound Medicine ER -